RA CAPITAL MANAGEMENT, L.P.

Q3 2025 13F Holdings

  • Location
    boston, MA
  • Num holdings

    67

  • Value ($000)

    $8,115,527

  • Date Filed
    11/14/2025
  • Form type
    13F-HR
  • CIK
    0001346824
  • All SEC filings
  • Note
    Holdings aggregated across “other managers” listed in original SEC filing, see here for detailed holdings broken out by other managers
Compare Q3 2025 to
Select Quarter
Issuer Name
Class
CUSIP
VALUE
%
Shares
Principal
Option Type
A
ASND

ASCENDIS PHARMA A/S - ADR

SH
04351P101
$2.04B
25 %

10,281,496

R
RYTM

RHYTHM PHARMACEUTICALS INC

SH
76243J105
$573.76M
7 %

5,681,359

P
PCVX

VAXCYTE INC

SH
92243G108
$431.01M
5 %

11,965,991

R
RNA

AVIDITY BIOSCIENCES INC

SH
05370A108
$376.49M
5 %

8,641,031

C
CDTX

CIDARA THERAPEUTICS INC

SH
171757206
$322.28M
4 %

3,365,523

---

SIONNA THERAPEUTICS INC

SH
829401108
$307.20M
4 %

10,445,322

E
ETNB

89BIO INC

SH
282559103
$292.38M
4 %

19,889,683

---

NEWAMSTERDAM PHARMA CO NV

SH
N62509109
$288.35M
4 %

10,138,938

M
MLYS

MINERALYS THERAPEUTICS INC

SH
603170101
$277.72M
3 %

7,323,750

J
JANX

JANUX THERAPEUTICS INC

SH
47103J105
$273.48M
3 %

11,189,693

Rows Per Page
10
  • 10
  • 50
  • 100
1 - 10 of 67